Medical staff test whether an Ebola protective suit is leak-proof at Shenzhen Third People's Hospital, in Shenzhen, Guangdong province, October 22, 2014. REUTERS/Stringer
Your feedback is important to us!
We invite all our readers to share with us their views and comments about this article.
Disclaimer: Comments submitted by third parties on this site are the sole responsibility of the individual(s) whose content is submitted. The Daily Star accepts no responsibility for the content of comment(s), including, without limitation, any error, omission or inaccuracy therein. Please note that your email address will NOT appear on the site.
Alert: If you are facing problems with posting comments, please note that you must verify your email with Disqus prior to posting a comment. follow this link to make sure your account meets the requirements. (http://bit.ly/vDisqus)
Drugmakers are looking for some kind of indemnity from governments or multilateral agencies against possible losses or claims arising from the widespread emergency use of new Ebola vaccines in Africa.There is currently no proven vaccine against Ebola and drug companies have been wary in the past of investing in the area, since the commercial opportunity is small.GSK currently has the most advanced vaccine, the first doses of which are expected to be ready for use late this year, while clinical trials on a second vaccine from NewLink Genetics have just started and Johnson & Johnson will commence testing a third one in January.
FOLLOW THIS ARTICLE